ENTA

Enanta Pharmaceuticals, Inc. Press Releases

$35.82
*  
1.06
2.87%
Get ENTA Alerts
*Delayed - data as of Feb. 27, 2015  -  Find a broker to begin trading ENTA now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Enanta Announces JAMA Publication of Results from AbbVie’s Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I)
2/23/2015 11:17:00 AM - Business Wire


Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) Published Online in JAMA; Sub-analyses to be Presented at the Annual Confere
2/23/2015 11:02:00 AM - PR Newswire


Enanta Announces AbbVie Submits New Drug Application to the Japanese Ministry of Health, Labour and Welfare for its Investigational, All-Oral, Treatment for Chronic Hepatitis C
2/12/2015 6:30:00 AM - Business Wire


AbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C
2/11/2015 10:04:00 PM - PR Newswire


Enanta Pharmaceuticals to Present at 2015 Leerink Global Healthcare Conference
2/5/2015 8:00:00 AM - Business Wire


Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2014
2/5/2015 7:30:00 AM - Business Wire


Enanta Announces 95 percent SVR12 rate in AbbVie’s Phase 3 Study of All-Oral Treatment for Hepatitis C Virus in Japanese Patients
2/2/2015 7:30:00 AM - Business Wire


AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan
1/30/2015 6:00:00 PM - PR Newswire


Enanta Announces European Commission Grants Marketing Authorizations for AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets)...
1/16/2015 7:00:00 AM - Business Wire
▼-26.52 % Price Change since this news event. The Volume Ratio is 0.57.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


European Commission Grants Marketing Authorizations for AbbVie''s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C
1/16/2015 2:00:00 AM - PR Newswire


European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C
1/16/2015 2:00:00 AM - PR Newswire


Enanta Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
1/7/2015 7:30:00 AM - Business Wire
▼-26.72 % Price Change since this news event. The Volume Ratio is 0.69.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Enanta Announces U.S. Food and Drug Administration Approves AbbVie’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus
12/19/2014 5:55:00 PM - Business Wire
▼-25.22 % Price Change since this news event. The Volume Ratio is 3.53.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C
12/19/2014 5:45:00 PM - PR Newswire


Enanta Pharmaceuticals Added to the NASDAQ Biotechnology Index
12/15/2014 8:19:00 AM - Business Wire
▼-21.93 % Price Change since this news event. The Volume Ratio is 1.64.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day